On November 25, 2025, the 5th "Sea Gathering Talents" Global Innovation and Entrepreneurship Summit was grandly opened at the West Bund International Convention and Exhibition Center in Shanghai. Chen Jining, Secretary of the Municipal Party Committee, attended the opening ceremony and launched the 6th "Gathering Talents by Sea" Global Innovation and Entrepreneurship Competition. At this summit, Dr. Wu Xiaoyun, founder of Immunowake Biopharmaceutical (Hangzhou) Co., Ltd., stood out from 14723 participating projects worldwide with his IL-12 immune agonist project targeting the tumor microenvironment, and won the Silver Award in the finals of the competition. This award signifies the high recognition of Longqi Biotechnology's original ability and technological advantages by the industry and experts, and also indicates that Longqi Biotechnology is at the forefront of the industry.

The "Gathering Talents by Sea" Global Innovation and Entrepreneurship Competition, as the highest level talent competition in Shanghai, has always been highly anticipated. Since its launch, the 5th "Sea Gathering Talents" Global Innovation and Entrepreneurship Competition has collected over 14000 projects from around the world. With the strongest organizational mobilization, the largest number of participating projects, the widest coverage, and the highest degree of internationalization, it has set several "firsts" in previous years. After multiple rounds of competition and rigorous evaluation, only 60 outstanding projects ultimately won awards, including 6 gold awards, 18 silver awards, and 36 bronze awards, with an award rate of only about 0.4%. Among them, there were more than 4300 projects in the life and health track, but only 10 won in the end, making the competition extremely fierce.

Immunowake Biotechnology was founded in 2022 and is a biotech company based on original innovation. It has a globally leading targeted cytokine technology platform and is committed to developing safer next-generation immune cytokines, significantly improving tumor cure rates and bringing hope for cure to advanced cancer patients. The company's first project is a targeted IL-12 immune agonist, which serves as a novel FIC drug with a cis acting mechanism. It specifically activates CD8 ⁺ T cells in tumors, blocks the inhibitory function of Treg cells, reverses the tumor immune suppressive microenvironment, and triggers an anti-tumor immune response in the body. This project has demonstrated excellent cure rates in late stage mouse tumor models, reversing PD-1 antibody resistance. Toxicological studies have confirmed its wide therapeutic window and high safety, and it is expected to break through the existing bottleneck of immunotherapy. At present, the project has submitted a pre IND application, and once clinically validated, its efficacy will surpass heavyweight drugs such as PD-1 inhibitors, leading the trillion dollar pharmaceutical market.